Protocol Development Groups
Protocol development groups (PDGs) can arise from research strategy workshops or are formed in response to funding calls or at the request of researchers. The IDRN provides administrative and academic support to protocol development groups and aims to ensure that the groups include appropriate multidisciplinary involvement. Protocol development groups provide an opportunity to explore potential research projects in more detail than is possible during research strategy days. Please contact us if you would like us to convene a group on your behalf.
Background work undertaken by the coordinating centre to support protocol development groups can include:- literature reviews to ensure the work is not duplicating existing work and to inform study design, conducting power calculations to assess the feasibility of projects, obtaining information on the likely numbers of patients available or conducting analyses of existing data that could inform the project.
A list of PDGs convened so far is below. If you attended a protocol development group, and require the minutes to be emailed to you, please contact us.
The groups that were convened are:
|
Risk factors and outcomes for hospital acquired antibiotic resistant infections
|
Relationship between prescribing, AMR & outcomes in neonatal intensive care units |
Hepatitis C transmission in HIV+ patients |
Chronic HCV/HIV observational study, pulling together non-APRICOT treatment outcomes |
Evaluation on no cephalosporin policy v alternative policy |
Surgical prophylaxis and antimicrobial resistance |
Immediate ARV vs deferred ARV in TB-HIV co-infected patient |
Molecular tests for diagnosing infection & AMR (meeting convened in response to HTA call for bids) |
Anti-microbial resistance & complexity approaches |
Health Survey for England and infectious diseases research |
What is the long term morbidity and mortality associated with IID? |
What is the natural history of Mycoplasma genitalium? |
Carriage and invasion of multiply resistant ESBL-producing strains of Escherichia coli |
Potential reduction of healthcare acquired infections, via decontamination methods |
IGRA use in tuberculosis disease |
| Scabies as a healthcare-associated infection 2 April, 25 September and 23 November 2009 |